Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Clinical Pharmacology and Therapeutics
|
March 25, 2015
Cannabinoids: Friend or foe?
B Le Foll, R F Tyndale
European Psychiatry : the Journal of the Association of European Psychiatrists
|
July 6, 2000
Dopamine D3 receptor agents as potential new medications for drug addiction
B Le Foll, J C Schwartz, P Sokoloff
Molecular Psychiatry
|
March 1, 2003
Disruption of nicotine conditioning by dopamine D(3) receptor ligands
B Le Foll, J-C Schwartz, P Sokoloff
European Psychiatry : the Journal of the Association of European Psychiatrists
|
September 21, 2005
Smoking cessation guidelines: evidence-based recommendations of the French Health Products Safety Agency
B Le Foll, P Melihan-Cheinin, G Rostoker, et al.
International Review of Neurobiology
|
April 9, 2016
Screening Medications for the Treatment of Cannabis Use Disorder
L V Panlilio, Z Justinova, J M Trigo, et al.
Journal De Toxicologie Clinique Et Experimentale
|
January 1, 1985
[Carpipramine and opipramol poisoning with ventricular tachycardia]
M Laurent, B Le Foll, A Rannou, et al.
Neurotoxicity Research
|
January 13, 2004
The dopamine D3 receptor and drug addiction
P Sokoloff, B Le Foll, S Perachon, et al.
Psychopharmacology
|
July 16, 2016
The agranular and granular insula differentially contribute to gambling-like behavior on a rat slot machine task: effects of inactivation and local infusion of a dopamine D4 agonist on reward expectancy
P J Cocker, M Y Lin, M M Barrus, et al.
CNS & Neurological Disorders Drug Targets
|
April 15, 2006
The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders
P Sokoloff, J Diaz, B Le Foll, et al.
Psychological Medicine
|
June 26, 2013
The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies
S Lev-Ran, M Roerecke, B Le Foll, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Clinical Pharmacology and Therapeutics
|
March 25, 2015
Cannabinoids: Friend or foe?
B Le Foll, R F Tyndale
European Psychiatry : the Journal of the Association of European Psychiatrists
|
July 6, 2000
Dopamine D3 receptor agents as potential new medications for drug addiction
B Le Foll, J C Schwartz, P Sokoloff
Molecular Psychiatry
|
March 1, 2003
Disruption of nicotine conditioning by dopamine D(3) receptor ligands
B Le Foll, J-C Schwartz, P Sokoloff
European Psychiatry : the Journal of the Association of European Psychiatrists
|
September 21, 2005
Smoking cessation guidelines: evidence-based recommendations of the French Health Products Safety Agency
B Le Foll, P Melihan-Cheinin, G Rostoker, et al.
International Review of Neurobiology
|
April 9, 2016
Screening Medications for the Treatment of Cannabis Use Disorder
L V Panlilio, Z Justinova, J M Trigo, et al.
Journal De Toxicologie Clinique Et Experimentale
|
January 1, 1985
[Carpipramine and opipramol poisoning with ventricular tachycardia]
M Laurent, B Le Foll, A Rannou, et al.
Neurotoxicity Research
|
January 13, 2004
The dopamine D3 receptor and drug addiction
P Sokoloff, B Le Foll, S Perachon, et al.
Psychopharmacology
|
July 16, 2016
The agranular and granular insula differentially contribute to gambling-like behavior on a rat slot machine task: effects of inactivation and local infusion of a dopamine D4 agonist on reward expectancy
P J Cocker, M Y Lin, M M Barrus, et al.
CNS & Neurological Disorders Drug Targets
|
April 15, 2006
The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders
P Sokoloff, J Diaz, B Le Foll, et al.
Psychological Medicine
|
June 26, 2013
The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies
S Lev-Ran, M Roerecke, B Le Foll, et al.
Page
of 2